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o Results demonstrate that the hydrodynamic conditions significantly affect the drug release kinetics of drugs from therapeutic contact lenses and that extrapolation of results obtained in static 
conditions to in vivo behaviour should be done with care. 
o Both systems seem to be promising for the production of drug loaded daily disposable soft contact lenses.  
 
Introduction 
Aims 
o The present work involves the development of a novel microfluidic cell designed to 
simulate the physiological conditions found in the eye (temperature, tear volume and 
flow rate) and therefore more appropriate to test the release of drugs from contact lenses 
materials.  
o Contact lenses were prepared with two types of materials: a hydroxyethylmethacrylate 
(HEMA) based hydrogel and a silicone based hydrogel. The former hydrogel was loaded 
with an antibiotic (levofloxacin, LVF) and the latter, with an antiseptic (chlorhexidine, 
CHX). 
Nowadays, over 90% of ophthalmic drugs are administered topically 
in the form of eye drops [1]. However, the residence time of the 
drug in the eye is short and only 1% to 7% of the administered drug 
is absorbed through the eye, leading to poor drug bioavailability 
and, in some instances, undesirable side effects [2]. 
 
 
 
In the last few years, efforts have been made to develop more 
efficient ocular drug delivery systems. Therapeutic soft contact 
lenses have demonstrated to be an ideal platform for the 
controlled delivery of numerous drugs as well as comfort 
molecules [3]. 
Typically, drug release experiments are conducted under static conditions but, under normal 
physiological conditions, the human eye presents a reduced tear volume and a tear turnover 
rate that varies between 1 and 4 µL/min. Thus, to study drug release kinetics in the eye, 
static conditions do not seem the most appropriate.  
TRIS/NVP/HEMA (40/40/20 , w/w) 
24h at 60°C 
o Two different types of hydrogels were prepared by thermal polymerization: 
 
 
o The hydrogels were loaded by soaking for 14 hours, at 4°C: HEMA/PVP was loaded with 
LVF (5 and 10 mg/mL solutions) and TRIS/NVP/HEMA with CHX (5 mg/mL solutions).  
o The experiments were carried out at 35°C using a microfluidic cell (image below) and in 
static conditions (2,6mL/lense) 
HEMA/PVP (98/2, w/w) 
overnight at 50°C,  followed by 24h at 70°C 
o The microfluidic cell was produced from poly(methyl methacrylate) (PMMA) and 
engineered to possess an inner chamber in contact with the hydrogel with a volume of 
45µL. Isotonic saline solution was allowed to flow directly over the drug loaded hydrogel 
with a volumetric flow rate of approximately 3µL/min, similar to that of the human eye. 
Aliquots were collected every hour. 
o The drug concentrations of the samples were determined by high performance liquid 
chromatography (LVF) and by spectrophotometry UV-Vis (CHX). 
o The values of the drug concentrations obtained under physiological ocular tear flow were 
compared with the minimum inhibitory concentrations (MIC) of the antibiotic LVF 
determined for S. aureus and P. aeruginosa, and of the antiseptic CHX for S. aureus. 
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Results and Discussion 
o The results obtained under physiological tear flow conditions using the microfluidic cell demonstrate in both cases (HEMA/PVP_LVF and TRIS/NVP/HEMA_CHX) extended drug release for a 
minimum of 3 days, while the experiments performed in static conditions, showed a maximum release time of 24 hours. 
o The comparison of the concentration profiles with the MICs shows that in the case of HEMA/PVP_LVF the concentration of the LVF loading solution had to be increased from 5mg/mL to 
10mg/mL, in order to exceed the MIC of Pseudomona aeruginosa, while for TRIS/NVP/HEMA_[CHX] 5 mg/mL, therapeutic levels  for Staphylococcus aureus were maintained along 7-10 hours. 
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